Not currently recruiting at UC Health
First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
Advanced Solid Tumor Non-Small Cell Lung Cancer Recurrent Squamous Cell Carcinoma of Head and Neck Non Small Cell Lung Cancer Metastatic Lung Neoplasms Carcinoma, Non-Small-Cell Lung Atezolizumab DRP-104
Lead Scientist at UC Health
- Aaron Lisberg, MD (ucla)
HS Assistant Clinical Professor, Medicine.
- accepting new patients
- Start Date
- Completion Date
- Dracen Pharmaceuticals, Inc.
- Company website with scientific background on DRP-104
- Phase 1/2
- Study Type
- Last Updated